treatment

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigatio..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated (NASDAQ: INSM) stock jumped about 113% on Tuesday, after the biopharmaceutical company announced top-line data from its Phase 3 CONVERT study.The company announced that the global CONVERT study met its primary endpoint of culture..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..